Program
JBI-778
Its studies are mostly in Carcinoma, Adenoid Cystic · Meningeal Neoplasms, led by 2 companies.
Furthest: phase 2, since Aug 3, 20262 company-led studies, 2 open or runningNext primary completion: Mar 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jubilant Therapeutics | 11 open or running | phase 2since Aug 3, 2026 | Aug 3, 2026 | Mar 31, 2030phase 2 · NCT07751744 |
| Jubilant Therapeutics India | 11 open or running | phase 1since Aug 5, 2026 | Aug 5, 2026 | Mar 2028phase 1 · NCT07755397 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 3, 2026First study: phase 2 study in Meningeal NeoplasmsNew to Jubilant TherapeuticsJubilant Therapeutics · NCT07751744 · 113 planned
- Aug 5, 2026Jubilant Therapeutics India’s first study: phase 1 study in NSCLC Patients With EGFR Activating MutationNew to Jubilant Therapeutics IndiaJubilant Therapeutics India · NCT07755397 · 30 planned · India
Ahead
- Mar 2028Primary completion: phase 1 study in NSCLC Patients With EGFR Activating MutationJubilant Therapeutics India · NCT07755397
- Mar 31, 2030Primary completion: phase 2 study in Meningeal NeoplasmsJubilant Therapeutics · NCT07751744
TargetBeta
PRMT5 →read by rule
“JBI-778 is an orally administered selective PRMT5 inhibitor supplied as capsules.”study text, by rule · the study
Other programs on PRMT5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| navlimetostat | Bristol-Myers Squibb | phase 3 | 10 |
| PRMT5 Inhibitor AZD3470 | AstraZeneca | phase 2 | 2 |
| PRMT5 Inhibitor TNG456rule | tango-therapeutics-inc | phase 2 | 1 |
| PRMT5 Inhibitor BAY 3713372rule | Bayer | phase 2 | 1 |
| onametostatrule | Johnson & Johnson | phase 1 | 2 |
| PRMT5 Inhibitor SH3765rule | Nanjing Sanhome Pharmaceutical | phase 1 | 2 |
| PRMT5 Inhibitor BGB-58067rule | BeOne Medicines | phase 1 | 2 |
| PRMT5 Inhibitor IDE892rule | ideaya-biosciences | phase 1 | 1 |
| PEP08rule | pharmaengine | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07755397NSCLC Patients With EGFR Activating Mutation · India | 1 | Recruiting | Jubilant Therapeutics India | Mar 2028 | 30 |
| NCT07751744Meningeal Neoplasms | 2 | Not yet recruiting | Jubilant Therapeutics | Mar 31, 2030 | 113 |
How it is read
Names in the registry
- “JBI-778”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Adenoid Cystic, 1 study
- Meningeal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.